Abbott Slaps Teva With Suit Over Generic AndroGel

Law360, New York (May 3, 2011, 3:01 PM EDT) -- An Abbott Laboratories unit hit Teva Pharmaceuticals USA Inc. with a patent suit Friday in Delaware over Teva’s bid to market its own version of AndroGel, a product at the center of ongoing antitrust battles over pay-for-delay settlements.

Abbott Products Inc. — joined by subsidiary Unimed Pharmaceuticals Inc., as well as Besins Healthcare Inc. — says that Teva had asked the U.S. Food and Drug Administration for approval to market a generic version of 1 percent AndroGel, in violation of a patent owned by Abbott and...
To view the full article, register now.